Loading...
XKRX
087010
Market cap2.18bUSD
Jul 10, Last price  
111,600.00KRW
1D
-29.94%
1Q
-58.28%
Jan 2017
470.11%
IPO
106.67%
Name

Peptron Inc

Chart & Performance

D1W1MN
XKRX:087010 chart
P/E
—
P/S
408.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.69%
Rev. gr., 5y
12.54%
Revenues
5.63b
+78.76%
3,100,534,0003,103,476,7202,483,532,2202,812,386,7713,130,705,2953,215,383,9943,861,733,2101,801,119,0003,120,698,0006,624,512,0005,813,995,5373,341,893,5723,152,181,0005,634,818,000
Net income
-13.82b
L-37.26%
-2,559,474,000-2,059,418,400-3,046,281,250-2,730,419,563-3,190,975,867-4,426,816,681-3,725,911,350-17,717,555,000-18,381,916,000-15,041,985,000-15,062,790,476-15,921,881,877-22,033,671,000-13,823,783,000
CFO
-20.59b
L+61.25%
-958,521,000-1,319,803,030-2,856,433,460-2,355,852,688-2,729,800,627-5,625,535,862-4,180,119,815-9,599,502,080-13,550,208,000-10,614,800,228-11,719,975,876-10,973,481,430-12,766,431,000-20,586,335,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Peptron, Inc. specializes in the creation of peptide-based pharmaceuticals designed to manage chronic health conditions. The company's technological expertise encompasses advanced long-acting drug delivery systems and SmartDepot, an ultrasonic spray-drying technique utilized for developing sustained-release injectable microsphere drug formulations. Their research and development pipeline features several key products: Luphere Depot, which addresses prostate cancer, endometriosis, uterine fibroids, and puberty-related issues; SR-Octreotide (PT201) for treating acromegaly; SR-Exenatide (PT302) for type 2 diabetes; and SR-Exenatide (PT320), which is aimed at Parkinson's and Alzheimer's diseases. Founded in 1997, Peptron, Inc. is headquartered in Daejeon, South Korea.
URL
http://www.peptron.co.kr/
IPO date
Jul 22, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT